Regimens for treating HIV infections and AIDS

US11564921B2 · kind B2 · utility

Assignees

• ViiV Healthcare Company · US
• Janssen Sciences Ireland Unlimited Company · IE

Inventors

• Herta CRAUWELS · Wilrijk, BE
• David Margolis · Yeadon, US
• William R. Spreen · Темневкий пруд, US
• Andrew Spaltenstein · Raleigh, US
• Peter Williams · Abington, GB

Key dates

• Filing date: Jul 18, 2018
• Grant date: Jan 31, 2023
• Expiry date: Jul 18, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.